Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$25.32 -0.5%	$22.52	$13.40 ▼ $25.88	$4.26B	0.7	2.18 million shs	563,818 shs
PHVS Pharvaris	$21.04 -0.3%	$19.37	$11.51 ▼ $26.33	$1.10B	-2.81	77,816 shs	12,709 shs
PTCT PTC Therapeutics	$47.90 +5.8%	$49.22	$30.41 ▼ $58.38	$3.81B	0.54	1.06 million shs	549,126 shs
ZLAB Zai Lab	$35.62 +3.8%	$36.77	$16.03 ▼ $44.34	$3.96B	1.03	990,631 shs	186,412 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+2.54%	+7.66%	+21.31%	+48.31%	+66.45%
PHVS Pharvaris	+1.20%	+0.43%	-16.04%	+31.24%	+34.08%
PTCT PTC Therapeutics	+4.55%	-11.43%	-6.76%	-3.17%	+44.59%
ZLAB Zai Lab	-1.01%	-13.16%	+4.83%	+21.93%	+110.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	3.9707 of 5 stars	3.3	3.0	0.0	2.1	4.2	2.5
PHVS Pharvaris	1.6261 of 5 stars	3.5	2.0	0.0	1.1	0.0	0.0
PTCT PTC Therapeutics	4.5606 of 5 stars	4.3	2.0	4.4	3.2	0.8	1.3
ZLAB Zai Lab	2.3546 of 5 stars	3.4	2.0	0.0	2.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.61	Moderate Buy	$28.88	14.04% Upside
PHVS Pharvaris	3.00	Buy	$35.60	69.24% Upside
PTCT PTC Therapeutics	2.63	Moderate Buy	$70.15	46.47% Upside
ZLAB Zai Lab	2.83	Moderate Buy	$57.22	60.66% Upside

Current Analyst Ratings Breakdown

Latest PHVS, PTCT, ZLAB, and ACAD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	PHVS Pharvaris	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$55.00 ➝ $52.00
8/11/2025	ZLAB Zai Lab	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$66.00 ➝ $69.00
8/8/2025	PTCT PTC Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$70.00
8/8/2025	PTCT PTC Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
8/8/2025	PTCT PTC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$60.00 ➝ $63.00
8/8/2025	ACAD ACADIA Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$32.00 ➝ $36.00
8/8/2025	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$78.00 ➝ $79.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	ACAD ACADIA Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$15.00 ➝ $17.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$39.00 ➝ $40.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $24.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$1.02B	4.19	$0.72 per share	35.21	$4.87 per share	5.20
PHVS Pharvaris	N/A	N/A	N/A	N/A	$5.54 per share	N/A
PTCT PTC Therapeutics	$1.76B	2.16	N/A	N/A	($2.60) per share	-18.42
ZLAB Zai Lab	$398.99M	9.92	N/A	N/A	$7.13 per share	5.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.33	19.01	33.32	6.32	21.80%	14.69%	9.41%	N/A
PHVS Pharvaris	-$145.24M	-$3.01	N/A	N/A	N/A	N/A	-54.02%	-50.36%	8/13/2025 (Estimated)
PTCT PTC Therapeutics	-$363.30M	$6.97	6.88	N/A	N/A	35.65%	-106.31%	30.61%	N/A
ZLAB Zai Lab	-$257.10M	-$2.04	N/A	N/A	N/A	-49.68%	-27.32%	-18.85%	N/A

Latest PHVS, PTCT, ZLAB, and ACAD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	PTCT PTC Therapeutics	-$1.07	-$0.83	+$0.24	-$0.83	$173.01 million	$178.88 million
8/7/2025	Q2 2025	ZLAB Zai Lab	-$0.37	-$0.37	N/A	-$0.37	$125.66 million	$109.98 million
8/6/2025	Q2 2025	ACAD ACADIA Pharmaceuticals	$0.14	$0.16	+$0.02	$0.16	$263.07 million	$264.57 million
5/13/2025	Q1 2025	PHVS Pharvaris	-$0.80	-$0.89	-$0.09	-$0.89	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.91	2.83
PHVS Pharvaris	N/A	11.10	11.10
PTCT PTC Therapeutics	N/A	3.62	3.85
ZLAB Zai Lab	N/A	3.12	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
PHVS Pharvaris	N/A
PTCT PTC Therapeutics	N/A
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	28.30%
PHVS Pharvaris	N/A
PTCT PTC Therapeutics	5.50%
ZLAB Zai Lab	4.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	168.71 million	120.97 million	Optionable
PHVS Pharvaris	30	52.29 million	N/A	Not Optionable
PTCT PTC Therapeutics	1,410	79.44 million	75.07 million	Optionable
ZLAB Zai Lab	1,869	111.08 million	105.57 million	Optionable

PHVS, PTCT, ZLAB, and ACAD Headlines

Recent News About These Companies

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Insider Rafael Amado Sells 3,000 Shares

August 13 at 6:10 AM | insidertrades.com

Zai Lab Ltd’s Earnings Call Highlights Growth and Profitability Path

August 13 at 5:07 AM | msn.com

US Bancorp DE Has $664,000 Stake in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

August 12 at 3:36 AM | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Issues Quarterly Earnings Results

August 10 at 9:22 PM | marketbeat.com

Here's What Analysts Are Forecasting For Zai Lab Limited (NASDAQ:ZLAB) After Its Second-Quarter Results

August 10 at 7:39 PM | finance.yahoo.com

Connor Clark & Lunn Investment Management Ltd. Buys 167,285 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

August 10 at 6:37 AM | marketbeat.com

Mackenzie Financial Corp Purchases New Stake in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

August 10 at 3:38 AM | marketbeat.com

XY Capital Ltd Invests $11.04 Million in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

August 9, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Down - Should You Sell?

August 8, 2025 | marketbeat.com

Zai Lab Limited (ZLAB) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Zai Lab reports Q2 EPS (4c), consensus (42c)

August 7, 2025 | msn.com

Zai Lab Misses Q2 Revenue Targets Despite EPS Beat; Shares Dip

August 7, 2025 | msn.com

Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

August 7, 2025 | zacks.com

This Cancer Treatment Stock Nears A Buy Point As Quarterly Results Loom

August 6, 2025 | investors.com

8,230 Shares in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Purchased by Bank of New York Mellon Corp

August 5, 2025 | marketbeat.com

Zai Lab (ZLAB) Projected to Post Earnings on Thursday

August 5, 2025 | americanbankingnews.com

DCF Advisers LLC Buys 25,250 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

August 4, 2025 | marketbeat.com

Privium Fund Management B.V. Trims Holdings in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

August 3, 2025 | marketbeat.com

Alberta Investment Management Corp Sells 36,031 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

August 3, 2025 | marketbeat.com

Short Interest in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Grows By 7,956.7%

August 2, 2025 | marketbeat.com

TD Asset Management Inc Lowers Position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

July 31, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHVS, PTCT, ZLAB, and ACAD Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$25.32 -0.13 (-0.51%)

As of 02:06 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Pharvaris NASDAQ:PHVS

$21.04 -0.06 (-0.26%)

As of 02:03 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

PTC Therapeutics NASDAQ:PTCT

$47.90 +2.63 (+5.80%)

As of 02:06 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Zai Lab NASDAQ:ZLAB

$35.62 +1.31 (+3.80%)

As of 02:05 PM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time